In conclusion, the combined assessment of metabolic changes using HP 13C pyruvate and 13C -glucose fluxomic could constitute an ideal multi-modal approach to assess response to BRAF/MEK inhibition in melanoma with specificity and sensitivity. The gene discussed is BRAF; the disease is melanoma.